Renovacor

Philadelphia, United States Founded: 2013 • Age: 13 yrs Acquired By Rocket Pharma
BAG3-related gene therapies for cardiovascular and CNS disorders are developed.

About Renovacor

Renovacor is a Healthcare company based in Philadelphia (United States) founded in 2013 by Arthur Feldman, and was acquired by Rocket Pharma in September 2022. BAG3-related gene therapies for cardiovascular and CNS disorders are developed. Renovacor has raised $11 million across 1 funding round from investors including Rocket Pharma, New Leaf Venture Partners and Novartis Venture Fund. Its chief executive, as recorded, is Magdalene Cook. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Drugs and Heart Failure. Its competitors include Kriya Therapeutics, Sana Biotechnology and PureTech Health; 3 of its 3 listed competitors have raised funding.

Company details

Renovacor was founded in 2013 in Philadelphia, United States, within the biotechnology sector. Emphasis is placed on drug development for cardiovascular and central nervous system disorders. BAG3-related gene therapies are pursued, including the candidate molecule REN-001, which remains in preclinical and research stages for cardiomyopathy and CNS indications. Operations center on advancing these therapies toward clinical applications.

  • Headquarters Philadelphia, United States
  • Founders Arthur Feldman
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website renovacor.com
  • Social LinkedIn X
  • Acquired by Rocket Pharma (Sep 2022)
Key Metrics
  • Net Profit
    -$780.77 K (USD)
    -150048
    as on Dec 31, 2020
  • EBITDA
    -$801.96 K (USD)
    -154123
    as on Dec 31, 2020
  • Total Equity Funding
    $11M (USD)

    in 1 rounds

  • Latest Funding Round
    $11M (USD), Series A

    Aug 2019

  • Investors
  • Acquired by
    Rocket Pharma

    (Sep 2022)

Funding Insights of Renovacor

Renovacor has successfully raised a total of $11M through 1 strategic funding round. The most recent funding activity was a Series A round of $11 million completed in August 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $11M
  • Total Rounds 1
  • Last Round Series A β€” $11M
  • First Round $11M

    (Aug 2019)

  • Investors Count 5

All 1 funding rounds of Renovacor with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Aug 2019$11MSeries A–Novartis Venture Fund, Broadview Ventures
Valuation history

6 investors in total: 6 institutional.

Investors in Renovacor

Renovacor has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include Rocket Pharma, New Leaf Venture Partners and Novartis Venture Fund.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Investments are made in innovative life science companies globally.
nvfund.comBasel, Switzerland
Seed-stage life sciences investments are made in the US.
broadviewventures.orgBoston, United States
bioadvance.com
VC firm investing in seed and early stage companies in Italy
innogestcapital.comMilan, Italy
Stage-agnostic investments in US life sciences are managed.
2005nlvpartners.comNew York, United States
Gene-modified cell therapies for rare diseases are developed.
2015rocketpharma.comNew York, United States
Premium access

Investor details for Renovacor

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Renovacor

23 people are tracked at Renovacor (8 in leadership, 12 in board & advisors, 3 in team).

NameRoleGroup
Arthur Feldman
FounderLeadership
Magdalene Cook
CEOLeadership
Valerie Myers
Senior Director, Preclinical DevelopmentLeadership
Beth White
Chief Business Officer & SVP, OperationsLeadership
Matt Killeen
Chief Scientific OfficerLeadership
Wendy DiCicco
CFOLeadership
Jiwen Zhang
Chief Regulatory OfficerLeadership
Marc Semigran
Chief Medical OfficerLeadership
Richard Peluso
Scientific AdvisorBoard & advisors
Jonas Grossman
DirectorBoard & advisors
Gregory F. Covino
DirectorBoard & advisors
Joan Lau
DirectorBoard & advisors
Gbola Amusa
DirectorBoard & advisors
Lee Sweeney
Scientific AdvisorBoard & advisors
Edward J Benz
DirectorBoard & advisors
Dennis McNamara
Scientific AdvisorBoard & advisors
Thomas Needham
DirectorBoard & advisors
Douglas Mann
Scientific AdvisorBoard & advisors
Joseph Glorioso III
Scientific AdvisorBoard & advisors
Michael Bristow
Scientific AdvisorBoard & advisors

3 more people are available in the full profile.

Premium access

Complete people profiles for Renovacor

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Renovacor

3 dated milestones of Renovacor across 9 years, from founding to its latest funding, stage changes and deals.

  1. Founded Renovacor is founded.
  2. Funding First funding round of $11.0M.
  3. Exit Acquired by Rocket Pharma.

Competitors of Renovacor

Renovacor has 3 listed competitors in our database, 3 of them funded. They include Kriya Therapeutics, Sana Biotechnology and PureTech Health.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
kriyatherapeutics.com2012Redwood, United States$930.93M159
Developer of therapeutic solutions for the treatment of diabetes
sana.com2018Seattle, United States$821M328
Genetically engineered cell therapies are developed for multiple disorders.
puretechhealth.com2001Boston, United States$107M171
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
Premium access

Detailed competitors of Renovacor

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Neurology

3 companies that operate in the same segment as Renovacor (Neurology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
2013San Francisco, California, United StatesUSD 214.78 MUSD 21.05 M211
Developer of therapeutics for psychiatric and neurologic diseases
2002New York, New York, United StatesUSD 80.87 MUSD 250.31 M600
Biologics platform developed for intracellular delivery in rare diseases.
2016Boston, Massachusetts, United StatesUSD 175.25 MUSD 25.42 M183
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Renovacor

Premium access

Complete news archive for Renovacor

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Renovacor

Renovacor was founded in 2013 and raised its 1st funding round 6 years after it was founded.

Renovacor is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.

Magdalene Cook is the CEO of Renovacor, as recorded in our data.

Renovacor is a funded company, having raised a total of $11M across 1 funding round to date. The company's 1st funding round was a Series A of $11M, raised on Aug 2019.

Renovacor was founded in 2013 in Philadelphia, United States, within the biotechnology sector. Emphasis is placed on drug development for cardiovascular and central nervous system disorders. BAG3-related gene therapies are pursued, including the candidate molecule REN-001, which remains in preclinical and research stages for cardiomyopathy and CNS indications. Operations center on advancing these therapies toward clinical applications.

Renovacor's top competitors include Sana Biotechnology, PureTech Health and Kriya Therapeutics.

Renovacor has 6 investors. Key investors include Rocket Pharma, New Leaf Venture Partners, Novartis Venture Fund, Broadview Ventures, and BioAdvance.

Yes. Renovacor was acquired by Rocket Pharma in September 2022.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available